Michael C. Hardy is a partner in Duane Morris' Corporate Practice Group and Co-Chair of the firm's Private Equity Division. He is the Managing Partner of the firm’s Baltimore office and a member of the firm's governing Partners Board.
Mr. Hardy’s practice focuses on representing capital providers and growth companies in connection with their most important transactions. He advises clients in connection with complex equity and debt financings, mergers and acquisitions and other strategic transactions both domestically and internationally. Mr. Hardy has extensive experience advising private equity sponsors, private credit funds, and portfolio companies funded by private capital across a broad range of industries.
Mr. Hardy's private capital clients include middle market equity and credit funds, large institutional investors, special situations funds, independent sponsors, SBICs and family offices. Mr. Hardy also regularly advises regulated financial institutions and borrowers in connection with lending transactions.
In addition to his private capital experience, Mr. Hardy has a broad-based multidisciplinary practice providing counsel to growth companies and middle market businesses. He advises management teams and boards of directors regarding strategic transactions, corporate governance and securities matters, business and tax strategy and matters relating to company operations. Mr. Hardy's corporate clients include companies in the technology, financial services, consumer products, telecommunications, education, real estate, healthcare and life sciences industries. Within the technology industry, Mr. Hardy has substantial experience with tech-enabled services, financial technology, cybersecurity, data analytics, healthcare and education technology companies.
Mr. Hardy is nationally recognized by clients and peers as a leader in mergers and acquisitions and private capital transactions. His insights about private equity and capital markets have appeared in numerous business and legal publications, including The Wall Street Journal, Bloomberg, Private Equity International, Regulatory and Compliance Watch and FundFire.
Mr. Hardy has been acknowledged by Chambers and Partners as a leader in Corporate and M&A and is rated as "Highly Regarded" by Euromoney's International Financial Law Review (IFLR). Mr. Hardy was a 2021 finalist for IFLR's National Private Equity Lawyer of the year and is recognized by The Best Lawyers in America in the field of Mergers & Acquisitions for 2022 and 2023. In 2022, he was selected by the Maryland Daily Record for inclusion in its Business and Employment Law Power List, which identifies power players across the state who are “leading key organizations, creating change, impacting the community and engaging others to succeed.”
Mr. Hardy is a graduate of Vanderbilt University Law School, and holds a business degree from Towson University.
Represented private equity firm Camden Partners in the $750 million sale of its portfolio company Ranir Global Holdings, the world's largest private label oral care company, to Perrigo Company PLC (NYSE, TASE: PRGO), a manufacturer of over-the-counter pharmaceuticals.
Represented a large multinational institutional investor as lead investor in connection with an $80 million preferred equity investment in a property management software company.
Represented a single-family office as lead investor in connection with a $23 million preferred equity investment in an immunotherapy biotechnology company.
Advised a middle market private equity fund in connection with the sale of its portfolio company, an international payment and transaction processing services business, for approximately $257 million.
Represented an SEC-registered alternative asset manager in the private credit space in connection with the negotiation and implementation of a $75 million construction equipment finance program platform.
Represented a multimedia entertainment company in connection with its recapitalization and issuance of $300 million of preferred stock to a private equity firm.
Advised a publicly traded investment fund as lead investor in a $115 million private placement of preferred stock by a transportation company.
Represented a private equity fund in connection with a series of preferred equity investments in a financial technology company totaling nearly $50 million.
Represented a private equity fund in connection with the sale of its interests in a healthcare technology portfolio company to affiliates of Kleiner Perkins for more than $35 million.
Advised an SEC-registered special situations investment fund in connection with a $46 million joint venture investment in a power generation facility.
Advised a leading global institutional investor in connection with its investment as lead investor in a $100 million private investment in public equity (PIPE) transaction.
Represented a biotechnology company in connection with its spinout from its corporate parent, issuance of preferred equity securities and subsequent acquisition and license of intellectual property assets relating to its business from MIT.
Represented a cybersecurity company in connection with its corporate restructuring and recapitalization and subsequent issuance of multiple tranches of preferred equity securities.
Advised a healthcare technology company in connection with its $110 million IPO.
Represented a leading natural personal care company in its cross-border sale to Australian conglomerate for total transaction value of more than $95 million; subsequently advised the seller's management team in connection with the treatment of rollover equity upon the acquisition of the buyer by Bain Capital.
Represented a Fortune Global 100 chemical company in connection with its multimillion-dollar cross-border acquisition of a nanomaterials company.
Advised a digital marketing company in connection with its corporate reorganization and multimillion-dollar recapitalization by ORIX Corporate Capital, multiple “roll-up” acquisitions and subsequent sale to Baird Capital.
Advised a closely held B2B assessment and training services company in connection with its sale to a leading environment, health and safety solutions company owned by CVC Growth Partners.
Represented the lead institutional investor in a publicly traded special purpose acquisition company (SPAC) in connection with the SPAC's merger and the surviving company's subsequent listing on the NASDAQ stock exchange at an enterprise value of approximately $850 million.
Advised an education software company in connection with its sale to News Corp. for $360 million.
Represented an independent private equity sponsor in connection with a platform company acquisition in the government services industry, subsequent "tuck-in" acquisitions and related equity and debt financing transactions in support of the acquisitions.
Represented an e-commerce company in connection with the sale of its intellectual property portfolio to Google, Inc.
Represented a special committee of the board of directors of a financial institution with respect to its fiduciary duties to stockholders in connection with a proposed sale of the bank holding company.
Advised investors and management in connection with the formation of a financial services software company, its venture financing and its acquisition of intellectual property and other assets from a bankrupt entity through a Section 363 sale process.
Advised a NASDAQ-listed telemedicine company and its board of directors and management in connection with its sale to a multinational healthcare products and services company for $428 million.
Represented a consumer electronics manufacturer in connection with its sale to a publicly traded consumer products company for $136 million.
Represented a telecommunications services company in connection with a senior secured syndicated ABL credit facility consisting of revolving and term loans from several large international banks and a subordinated term loan from private investors.
Advised one of the nation's leading banks in connection with multiple syndicated lending transactions to large corporate borrowers.
Represented an SBIC mezzanine-lending fund in connection with its investment in a manufacturing company through subordinated debt and equity securities.
Represented a mezzanine-lending fund in connection with its debt and equity investment in a business services company.
Represented a leading national bank in connection with numerous commercial and industrial loans.
Private Equity and Securities
Mergers & Acquisitions
- District of Columbia
- Vanderbilt University Law School, J.D.
- Associate Editor, Vanderbilt Journal of Entertainment Law & Practice
- Towson University, B.S., Economics and Political Science
- Duane Morris LLP
- Partner, 2017-present
Prior to joining Duane Morris, Mr. Hardy practiced law as an associate and then partner at several prominent international law firms.
During law school, Mr. Hardy worked for Vice Chancellors Stephen Lamb and Leo Strine of the Delaware Court of Chancery, as well as for the Honorable Thomas A. Wiseman Jr., of the United States District Court for the Middle District of Tennessee.
Before attending law school, Mr. Hardy ran a small business and worked during college as a Congressional intern on Capitol Hill.
- Association for Corporate Growth, Maryland Chapter
- Board and Executive Committee Member
- Maryland State Bar Association
- Business Law Section
- Chair, Middle Market Committee
- American Bar Association
- Bar Association of the District of Columbia
Honors and Awards
- Named to Maryland Daily Record’s 2022 Business Law Power List
- Listed in The Best Lawyers in America, 2022-2024
- Listed in Chambers USA, 2016-2017 and 2020-2023
- Rated as "Highly Regarded" for M&A and Private Equity by IFLR1000 2020-2022
- Finalist – Private Equity Lawyer of the Year – IFLR United States Awards, 2021
- 40 Under 40 Award Nominee, Maryland Daily Record
- 35 Under 35 Award Honoree, Cystic Fibrosis Foundation
Civic and Charitable Activities
- Project Opportunity Veterans Program, Mentor and Guest Lecturer
- Best Buddies International, Maryland Chapter
- Past Member, Board of Advisors
- Cystic Fibrosis Foundation
- Leukemia & Lymphoma Society Light the Night Walk
- Member, Executive Committee, 2012
- Co-author, "New Marketing Rule Under the Investment Advisers Act – Compliance Date Is Approaching," Duane Morris Alert, October 17, 2022
Author, "A Qualified Opinion: Growing Emphasis on Cost Control and Value-Based Care is Driving Consolidation and Creating New Opportunities for PE Investors," Middle Market Growth, May/June 2019
- Featured as a "Featured Mover" in The Daily Record, March 7, 2023
- Quoted, "'Red Ripple' Gives SEC a Green Light," PEI Manager, November 21, 2022
- Quoted, "Private Equity Scrambles to Comply With SEC Marketing Rule as Deadline Nears," The Wall Street Journal, October 24, 2022
- Quoted, "Managers Still Making 'Last Minute' Calls on New SEC Marketing Rule ," FundFire, September 21, 2022
- Quoted, "Don't Wait for GOP, Veteran Advocate Urges," Regulatory Compliance Watch, August 18, 2022
- Quoted, "SPAC Smart Money Jilts $27 Billion of New Blank-Check Offerings," Bloomberg, May 11, 2022
- Featured, "Rainmakers: Md. Lawyers at the Top of Their Game Discuss Their Journey," Maryland Daily Record, April 12, 2019